STOCK TITAN

[SCHEDULE 13G/A] Forrester Research Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

On 07/15/2025, CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. jointly filed a Schedule 13G reporting a passive ownership of 1,000,000 BriaCell Therapeutics Corp. common shares (CUSIP 107930208). The stake equals 5.7 % of the 17.55 M shares outstanding, as cited in BriaCell’s July 2025 prospectus. Each Reporting Person claims 0 sole and 1,000,000 shared voting and dispositive power. Both entities disclaim beneficial ownership beyond their pecuniary interest and certify the shares were not acquired to influence control. Signatory: Sarah Travis (Heights Capital) on 07/22/2025. No group arrangements, subsidiaries, or additional controlling interests are disclosed.

Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G, segnalando una partecipazione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La quota rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ogni soggetto segnalante dichiara di detenere 0 poteri di voto e dispositivi esclusivi e 1.000.000 condivisi. Entrambe le entità negano la titolarità effettiva oltre il loro interesse economico e certificano che le azioni non sono state acquisite per influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o ulteriori interessi di controllo.

El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una participación pasiva de 1.000.000 de acciones ordinarias de BriaCell Therapeutics Corp. (CUSIP 107930208). La participación equivale al 5,7% de las 17,55 millones de acciones en circulación, según el prospecto de BriaCell de julio de 2025. Cada persona informante declara tener 0 poderes de voto y disposición exclusivos y 1.000.000 compartidos. Ambas entidades niegan la propiedad beneficiaria más allá de su interés económico y certifican que las acciones no fueron adquiridas para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se divulgan acuerdos de grupo, subsidiarias ni intereses de control adicionales.

2025년 7월 15일, CVI Investments, Inc.와 투자 관리자 Heights Capital Management, Inc.가 공동으로 Schedule 13G를 제출하여 1,000,000주 BriaCell Therapeutics Corp. 보통주(CUSIP 107930208)에 대한 수동적 소유권을 보고했습니다. 이 지분은 BriaCell의 2025년 7월 투자설명서에 명시된 총 17.55백만 주의 5.7%에 해당합니다. 각 보고자는 단독 의결권 및 처분권 0주공동 의결권 및 처분권 1,000,000주를 주장합니다. 두 기관 모두 금전적 이익을 넘어선 실질적 소유권을 부인하며, 주식이 지배권 영향 목적으로 취득되지 않았음을 인증합니다. 서명자: Sarah Travis (Heights Capital), 2025년 7월 22일. 그룹 협약, 자회사 또는 추가 지배권은 공개되지 않았습니다.

Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d’investissement Heights Capital Management, Inc. ont conjointement déposé un Schedule 13G déclarant une possession passive de 1 000 000 d’actions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation représente 5,7 % des 17,55 millions d’actions en circulation, comme indiqué dans le prospectus de BriaCell de juillet 2025. Chaque personne déclarant revendique 0 pouvoir de vote et de disposition exclusif et 1 000 000 partagés. Les deux entités déclinent toute propriété bénéficiaire au-delà de leur intérêt pécuniaire et certifient que les actions n’ont pas été acquises pour influencer le contrôle. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiales ou intérêts de contrôle supplémentaires ne sont divulgués.

Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein, in dem sie einen passiven Besitz von 1.000.000 Stammaktien der BriaCell Therapeutics Corp. (CUSIP 107930208) meldeten. Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verfügungsrechte. Beide Einheiten lehnen eine wirtschaftliche Eigentümerschaft über ihr finanzielles Interesse hinaus ab und bestätigen, dass die Aktien nicht zur Einflussnahme auf die Kontrolle erworben wurden. Unterzeichner: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.

Positive
  • Institutional ownership disclosed: CVI Investments & Heights Capital now publicly report a 5.7 % stake (1 M shares), increasing transparency of BriaCell’s shareholder base.
Negative
  • None.

Insights

TL;DR: 5.7 % passive stake disclosed; institutional holder presence is neutral-to-slightly positive, no control intentions stated.

The filing introduces CVI/Heights Capital as a mid-sized shareholder, now above the 5 % reporting threshold. Shared, not sole, authority implies a coordinated but non-controlling position. Because the investment is certified as passive, no immediate strategic shift or activist pressure should be expected. From a liquidity perspective, 1 M shares represent modest ownership relative to BriaCell’s float, signalling limited market impact. Overall, disclosure enhances transparency but is not materially transformational.

TL;DR: Disclosure improves ownership clarity; passive stance lowers governance risk—overall neutral governance impact.

Schedule 13G confirms the investors’ passive status under Rule 13d-1(c), alleviating concerns of an unsolicited takeover attempt. Shared voting/dispositive power is typical for an investment manager structure and aligns with SEC requirements. The disclaimer of beneficial ownership beyond pecuniary interest further limits potential governance influence. No group formation, subsidiary involvement, or control-seeking language appears, suggesting standard institutional investment behaviour.

Il 15/07/2025, CVI Investments, Inc. e il suo gestore degli investimenti Heights Capital Management, Inc. hanno presentato congiuntamente un Schedule 13G, segnalando una partecipazione passiva di 1.000.000 di azioni ordinarie di BriaCell Therapeutics Corp. (CUSIP 107930208). La quota rappresenta il 5,7% delle 17,55 milioni di azioni in circolazione, come indicato nel prospetto di BriaCell di luglio 2025. Ogni soggetto segnalante dichiara di detenere 0 poteri di voto e dispositivi esclusivi e 1.000.000 condivisi. Entrambe le entità negano la titolarità effettiva oltre il loro interesse economico e certificano che le azioni non sono state acquisite per influenzare il controllo. Firmataria: Sarah Travis (Heights Capital) il 22/07/2025. Non sono stati dichiarati accordi di gruppo, controllate o ulteriori interessi di controllo.

El 15/07/2025, CVI Investments, Inc. y su gestor de inversiones Heights Capital Management, Inc. presentaron conjuntamente un Schedule 13G reportando una participación pasiva de 1.000.000 de acciones ordinarias de BriaCell Therapeutics Corp. (CUSIP 107930208). La participación equivale al 5,7% de las 17,55 millones de acciones en circulación, según el prospecto de BriaCell de julio de 2025. Cada persona informante declara tener 0 poderes de voto y disposición exclusivos y 1.000.000 compartidos. Ambas entidades niegan la propiedad beneficiaria más allá de su interés económico y certifican que las acciones no fueron adquiridas para influir en el control. Firmante: Sarah Travis (Heights Capital) el 22/07/2025. No se divulgan acuerdos de grupo, subsidiarias ni intereses de control adicionales.

2025년 7월 15일, CVI Investments, Inc.와 투자 관리자 Heights Capital Management, Inc.가 공동으로 Schedule 13G를 제출하여 1,000,000주 BriaCell Therapeutics Corp. 보통주(CUSIP 107930208)에 대한 수동적 소유권을 보고했습니다. 이 지분은 BriaCell의 2025년 7월 투자설명서에 명시된 총 17.55백만 주의 5.7%에 해당합니다. 각 보고자는 단독 의결권 및 처분권 0주공동 의결권 및 처분권 1,000,000주를 주장합니다. 두 기관 모두 금전적 이익을 넘어선 실질적 소유권을 부인하며, 주식이 지배권 영향 목적으로 취득되지 않았음을 인증합니다. 서명자: Sarah Travis (Heights Capital), 2025년 7월 22일. 그룹 협약, 자회사 또는 추가 지배권은 공개되지 않았습니다.

Le 15/07/2025, CVI Investments, Inc. et son gestionnaire d’investissement Heights Capital Management, Inc. ont conjointement déposé un Schedule 13G déclarant une possession passive de 1 000 000 d’actions ordinaires de BriaCell Therapeutics Corp. (CUSIP 107930208). Cette participation représente 5,7 % des 17,55 millions d’actions en circulation, comme indiqué dans le prospectus de BriaCell de juillet 2025. Chaque personne déclarant revendique 0 pouvoir de vote et de disposition exclusif et 1 000 000 partagés. Les deux entités déclinent toute propriété bénéficiaire au-delà de leur intérêt pécuniaire et certifient que les actions n’ont pas été acquises pour influencer le contrôle. Signataire : Sarah Travis (Heights Capital) le 22/07/2025. Aucun accord de groupe, filiales ou intérêts de contrôle supplémentaires ne sont divulgués.

Am 15.07.2025 reichten CVI Investments, Inc. und ihr Investmentmanager Heights Capital Management, Inc. gemeinsam ein Schedule 13G ein, in dem sie einen passiven Besitz von 1.000.000 Stammaktien der BriaCell Therapeutics Corp. (CUSIP 107930208) meldeten. Der Anteil entspricht 5,7 % der 17,55 Mio. ausstehenden Aktien, wie im Juli 2025 Prospekt von BriaCell angegeben. Jede meldende Person beansprucht 0 alleinige und 1.000.000 gemeinsame Stimm- und Verfügungsrechte. Beide Einheiten lehnen eine wirtschaftliche Eigentümerschaft über ihr finanzielles Interesse hinaus ab und bestätigen, dass die Aktien nicht zur Einflussnahme auf die Kontrolle erworben wurden. Unterzeichner: Sarah Travis (Heights Capital) am 22.07.2025. Es werden keine Gruppenvereinbarungen, Tochtergesellschaften oder weitere Kontrollinteressen offengelegt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



ROYCE & ASSOCIATES LP
Signature:Daniel A. O'Byrne
Name/Title:Vice President
Date:07/22/2025
Exhibit Information

The securities reported herein are beneficially owned by one or more registered investment companies or other managed accounts that are investment management clients of Royce & Associates, LP ("RALP"), an indirect majority owned subsidiary of Franklin Resources, Inc.("FRI"). When an investment management contract (including a sub advisory agreement) delegates to RALP investment discretion or voting power over the securities held in the investment advisory accounts that are subject to that agreement, FRI treats RALP as having sole investment discretion or voting authority, as the case may be, unless the agreement specifies otherwise. Accordingly, RALP reports on Schedule 13G that it has sole investment discretion and voting authority over the securities covered by any such investment managementagreement, unless otherwise noted in this Item 4. As a result, for purposes of Rule 13d 3 under the Act, RALP may be deemed to be the beneficial owner of the securities reported in this Schedule 13G. Beneficial ownership by investment management subsidiaries and other affiliates of FRI is being reported in conformity with the guidelines articulated by the SEC staff in Release No. 3439538 (January 12, 1998) relating to organizations, such as FRI, where related entities exercise voting and investment powers over the securities being reported independently from eachother. The voting and investment powers held by RALP are exercised independently from FRI(RALP's parent holding company) and from all other investment management subsidiaries of FRI (FRI, its affiliates and investment management subsidiaries other than RALP are, collectively, "FRI affiliates"). Furthermore, internal policies and procedures of RALP and FRI affiliates establish informational barriers that prevent the flow between RALP and the FRI affiliates of information that relates to the voting and investment powers over the securities owned by their respective investment management clients. Consequently, RALP and the FRI affiliates report the securities over which they hold investment and voting power separately from each other for purposes of Section 13 of the Act. Charles B. Johnson and Rupert H. Johnson, Jr. (the "Principal Shareholders") may each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI (see FRI's Proxy Statement-Stock Ownership of Certain Beneficial Owners). However, because RALP exercises voting and investment powers on behalf of its investment management clients independently of FRI affiliates, beneficial ownership of the securities reported by RALP is not attributed to the Principal Shareholders. RALP disclaims any pecuniary interest in any of the securities reported in this Schedule 13G. In addition, the filing of this Schedule 13G on behalf of RALP should not be construed as an admission that it is, and it disclaims that it is, the beneficial owner, as defined in Rule 13d 3, of any of such securities. Furthermore, RALP believes that it is not a "group" with FRI affiliates, the Principal Shareholders, or their respective affiliates within the meaning of Rule 13d 5 under the Act and that none of them is otherwise required to attribute to any other the beneficial ownership of the securities held by such person or by any persons or entities for whom or for which RALP or the FRI affiliates provide investment management services.

FAQ

How many BriaCell (BCTXZ) shares do CVI Investments and Heights Capital own?

They report 1,000,000 common shares of BriaCell Therapeutics Corp.

What percentage of BriaCell’s outstanding shares does the 1 M-share position represent?

The filing states the stake equals 5.7 % of BriaCell’s outstanding common shares.

Is the CVI/Heights Capital position passive or activist?

The Schedule 13G certification confirms the shares were acquired passively, with no intent to influence control.

Do CVI Investments or Heights Capital hold sole voting power over the shares?

No. They report 0 sole and 1,000,000 shared votes and dispositive power.

When was the event triggering the Schedule 13G filing?

The relevant event date is 07/15/2025, as disclosed in the filing.
Forrester Resh Inc

NASDAQ:FORR

FORR Rankings

FORR Latest News

FORR Latest SEC Filings

FORR Stock Data

181.67M
11.34M
40.24%
54.5%
0.83%
Consulting Services
Services-engineering, Accounting, Research, Management
Link
United States
CAMBRIDGE